labmt: impact of treatment prior to allogenic hct in mds
Published 4 years ago • 40 plays • Length 4:31Download video MP4
Download video MP3
Similar videos
-
5:43
pre- and post-allohsct treatment in mds
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
2:44
the impact of mutation screening on transplant decisions in mds
-
2:04
state-of-the-art treatment for hr-mds
-
1:17
the curative potential of allosct in the treatment of hr-mds
-
7:54
patient/caregiver stories - living with mds
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
2:16
updates in the myelodysplastic syndromes: 2023 best of hematology
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
1:59
topics of interest in mds: the role of maintenance therapy, immune checkpoints & ven-aza in hr-mds
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
2:43
novel therapies in the future of mds treatment
-
1:16
state of the art: mds
-
0:41
the role of transplantation in mds
-
1:45
updates on the treatment of mds
-
1:58
therapy-related mds
-
2:25
jairus ibabao, md | medical oncology and hematology
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
1:51
checkpoint inhibition in the treatment of mpns
-
1:20
the current standard of care for patients with lower-risk mds
-
2:02
safety and efficacy of cd45ra -depleted dli in pediatric stem cell transplant recipients
-
1:34
personalizing treatment of transfusion-dependent anemia in lr-mds